Reproducibility of PET measurement for presynaptic dopaminergic functions using L-[β-11C]DOPA and [18F]FE-PE2I in humans

Nuclear Medicine Communications

Volumn 35, Issue 3, 2014, Pages 231-237

  Suzuki, Masayuki ^a,b   Ito, Hiroshi ^a   Kodaka, Fumitoshi ^a   Takano, Harumasa ^a   Kimura, Yasuyuki ^a   Fujiwara, Hironobu ^a   Sasaki, Takeshi ^a   Takahata, Keisuke ^a   Nogami, Tsuyoshi ^a   Nagashima, Tomohisa ^a   Nengaki, Nobuki ^a   Kawamura, Kazunori ^a   Zhang, Ming Rong ^a   Varrone, Andrea ^c   Halldin, Christer ^c   Okubo, Yoshiro ^b   Suhara, Tetsuya ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

18F FE PE2I; dopamine synthesis; dopamine transporter; L 11C DOPA; positron emission tomography

Indexed keywords

DOPAMINE TRANSPORTER; FE PE2L F 18; L [BETA]DOPA CARBON 11; TRACER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CAUDATE NUCLEUS; CORPUS STRIATUM; CORRELATION COEFFICIENT; DOPAMINE UPTAKE; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; HUMAN; HUMAN EXPERIMENT; MALE; MESENCEPHALON; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PUTAMEN; REPRODUCIBILITY; TEST RETEST RELIABILITY; THALAMUS; YOUNG ADULT;

ADULT; CARBON RADIOISOTOPES; DIHYDROXYPHENYLALANINE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; MALE; MESENCEPHALON; NEOSTRIATUM; NORTROPANES; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; SYNAPSES; YOUNG ADULT;

EID: 84893547076     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0000000000000052     Document Type: Article

References (34)

1. Korf J, Reiffers S, Beerling-Van Der Molen H, Lakke J, Paans A, Vaalburg W, et al. Rapid decarboxylation of carbon-11 labelled DL-DOPA in the brain: a potential approach for external detection of nervous structures. Brain Res 1978; 145:59-67.
2. 11C]-L-3, 4-dihydroxy-phenylalanine (DOPA) in the primate by positron emission tomography. Acta Neurol Scand 1992; 85:166-173.
3. 11C]dopa in humans studied by positron emission tomography. J Neural Transm 1991; 86:25-41.
4. 123I]b-CIT. Binding kinetics in the human brain. J Neural Transm 1993; 94:137-146.
5. Kuikka JT, Bergström KA, Ahonen A, Hiltunen J, Haukka J, Länsimiese E, et al. Comparison of iodine-123 labelled 2b-carbomethoxy-3b- (4-iodophenyl) tropane and 2b-carbomethoxy-3b-(4-iodophenyl)-N-(3-fluoropropyl) nortropane for imaging of the dopamine transporter in the living human brain. Eur J Nucl Med 1995; 22:356-360.
6. 18F]FE-PE2I, a new dopamine transporter PET radioligand. Synapse 2009; 63:871-880.
7. 18F]FE-PE2I, a new probe for the dopamine transporter. Bioorg Med Chem Lett 2009; 19:4843-4845.
8. 3H- labeled N-(3-iodoprop-2E-enyl)-2beta-carbomethoxy-3beta-(4-methylphenyl) nortropane (PE2I) and its interaction with mice striatal membrane fragments. Appl Radiat Isot 2007; 65:293-300.
9. 18F-FE-PE2I. J Nucl Med 2012; 53:1065-1073.
10. 18F-FE-PE2I. J Nucl Med 2011; 52:132-139.
11. 11C]-DOPA PET studies. Schizophr Bull 2013; 39:33-42.
12. 11C]DOPA PET. Schizophr Res 2009; 108:78-84.
13. 11C]PE2I in patients with schizophrenia: a positron emission tomography study of dopamine transporter. J Psychiatr Res 2009; 43:1219-1223.
14. 11C]DOPA. Life Sci 2006; 79:730-736.
15. Matsumoto K, Kitamura K, Mizuta T, Tanaka K, Yamamoto S, Sakamoto S, et al. Performance characteristics of a new 3-dimensional continuous-emission and spiral-transmission high-sensitivity and high-resolution PET camera evaluated with the NEMA NU 2-2001 standard. J Nucl Med 2006; 47:83-90.
16. Ishikawa A, Kitamura K, Mizuta T, Tanaka K, Amano M, Inoue Y, et al. Implementation of on-the-fly scatter correction using dual energy window method in continuous 3D whole body PET scanning. Nucl Sci Symp Conf Rec 2005; 5:2497-2500.
17. 11C]DOPA. Nucl Med Commun 2006; 27:723-731.
18. Gjedde A. Exchange diffusion of large neutral amino acids between blood and brain. New York: Stockton Press; 1988.
19. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985; 5:584-590.
20. Brown RM, Crane AM, Goldman PS. Regional distribution of monoamines in the cerebral cortex and subcortical structures of the rhesus monkey: concentrations and in vivo synthesis rates. Brain Res 1979; 168:133-150.
21. Lloyd K, Hornykiewicz O. Occurrence and distribution of aromatic L-amino acid (L-DOPA) decarboxylase in the human brain. J Neurochem 1972; 19:1549-1559.
22. 11C]DOPA. Ann Nucl Med 2007; 21:355-360.
23. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage 1996; 4:153-158.
24. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27:1533-1539.
25. Fleiss JL. The design and analysis of clinical experiments. New York: Wiley; 1986.
26. Ito H, Takahashi H, Arakawa R, Takano H, Suhara T. Normal database of dopaminergic neurotransmission system in human brain measured by positron emission tomography. Neuroimage 2008; 39:555-565.
27. Vingerhoets FJ, Snow BJ, Schulzer M, Morrison S, Ruth TJ, Holden JE, et al. Reproducibility of fluorine-18-6-fluorodopa positron emission tomography in normal human subjects. J Nucl Med 1994; 35:18-24.
28. 11C]PE2I: quantitative modeling and test-retest reproducibility. J Cereb Blood Flow Metab 2008; 28:1059-1069.
29. Seibyl JP, Laruelle M, van Dyck CH, Wallace E, Baldwin RM, Zoghbi S, et al. Reproducibility of iodine-123-b-CIT SPECT brain measurement of dopamine transporters. J Nucl Med 1996; 37:222-228.
30. 123I-FPCIT SPECT in normal control and Parkinson's disease patients. Ann Nucl Med 2004; 18:609-616.
31. 18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996; 119:585-591.
32. Pirker W, Djamshidian S, Asenbaum S, Gerschlager W, Tribl G, Hoffmann M, et al. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal b-CIT SPECT study. Mov Disord 2002; 17:45-53.
33. Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 2000; 47:493-503.
34. Eshuis S, Jager P, Maguire R, Jonkman S, Dierckx R, Leenders K. Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls. Eur J Nucl Med 2009; 36:454-462.